Liver magnetic resonance imaging for evaluation of response to treatment after stereotactic body radiation therapy of hepatocellular carcinoma

Table 1 Magnetic resonance imaging characteristics at pre- and post- stereotactic body radiation therapy follow-ups

	End of SBRT	1° MRI FU	(Pre vs 1°FU)	2° MRI FU	(1° vs 2°FU)
T (mo)	0	4.1 (3.1- 6.7)	< 0.0001	9.3 (6.2-12.3)
Arterious D	17 (12-24)	0 (0-16)	< 0.0001	0 (0-0)	< 0.005
T1-weighted D	17 (12-23)	13 (11-21)	< 0.0001	11 (8-17)	< 0.005
HBP D	17 (13-24)	13 (10-19)	< 0.0001	10 (7-16)	< 0.005
Average D	17 (13-24)	13 (11-20)		10 (7-15)	< 0.009
ADC	1.0	1.4	< 0.0006	1.4	0.19
T2-weighted hyperintensity	38 (62%)	18 (30%)	< 0.0001	9 (25%)	0.81
DWI	41 (68%)	11 (18%)		3 (9%)	0.34
Ring enhancement		50 (82%)		25 (69%)	0.24
Perilesional T2 hyp		51 (84%)		27 (75%)	0.44
HBP band-like		58 (95%)		34 (94%)	0.74
Capsular retraction		20 (33%)		23 (64%)	0.006
Infield progression		3 (5%)		1 (3%)
Outfield progression		11 (18%)		10 (28%)

SBRT: Stereotactic body radiation therapy; FU: Follow-up; MRI: Magnetic resonance imaging; T: Time; D: Diameter; HBP: Hepatobiliary phase; ADC: Apparent diffusion coefficient; DWI: Diffusion-weighted imaging.